← Leaderboards
Rheem Angela Totah
University Of Washington
$7,253,628
Attributed
$12,828,980
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,828,980 · 5
By mechanism
R01$12,828,980 · 5
Top collaborators
- Rozenn Lemaitre8 shared
- Nona Sotoodehnia8 shared
Most similar at University Of Washington
Same institution · by research overlap
- Judith N. Wasserheit$2,842,926
- Wesley C Van Voorhis$32,631,211
- Junko Oshima$3,761,782
- Elaine M Faustman$18,418,102
- Ian Amos Glass$13,073,291
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventCardiac MyocytesMediatingVentricularAnabolismToxic EffectCardiacSamplingMyocardial InfarctionRisk FactorsApoptosisLinkReactive Oxygen SpeciesFunctional DisorderPlasmaInnovationMuscle CellsEnzymesPathway InteractionsResponsePopulation BasedPublic HealthMortalityAtherosclerosis
Grant awards (21)
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$655,186
R01 · FY2025 · HL · contact PI
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$641,276
R01 · FY2024 · HL · contact PI
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$655,329
R01 · FY2023 · HL · contact PI
Sudden cardiac arrest and circulating hydrogen sulfide$714,436
R01 · FY2022 · HL · contact PI
Circulating hydrogen sulfide, diabetes and diabetes-related cardiovascular disease$673,106
R01 · FY2022 · HL · contact PI
Sudden cardiac arrest and circulating hydrogen sulfide$714,436
R01 · FY2021 · HL · contact PI
Sudden cardiac arrest and circulating hydrogen sulfide$714,436
R01 · FY2020 · HL · contact PI
Sudden cardiac arrest and circulating hydrogen sulfide$714,436
R01 · FY2019 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$668,957
R01 · FY2019 · HL
CYP2J2 Mediated Eicosanoids in Arrhythmias and Sudden Cardiac Arrest$721,142
R01 · FY2018 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$696,593
R01 · FY2018 · HL
CYP2J2 Mediated Eicosanoids in Arrhythmias and Sudden Cardiac Arrest$721,142
R01 · FY2017 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$702,829
R01 · FY2017 · HL
CYP2J2 Mediated Eicosanoids in Arrhythmias and Sudden Cardiac Arrest$720,442
R01 · FY2016 · HL · contact PI
Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease$701,774
R01 · FY2016 · HL
CYP2J2 Mediated Eicosanoids in Arrhythmias and Sudden Cardiac Arrest$735,184
R01 · FY2015 · HL · contact PI
Role of CYP2J2 in Xenobiotic Induced QT-prolongation$332,190
R01 · FY2014 · HL · contact PI
Role of CYP2J2 in Xenobiotic Induced QT-prolongation$323,230
R01 · FY2013 · HL · contact PI
Role of CYP2J2 in Xenobiotic Induced QT-prolongation$340,048
R01 · FY2012 · HL · contact PI
Role of CYP2J2 in Xenobiotic Induced QT-prolongation$343,974
R01 · FY2011 · HL · contact PI
Role of CYP2J2 in Xenobiotic Induced QT-prolongation$338,834
R01 · FY2010 · HL · contact PI